HC Wainwright Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to "Buy"

HC Wainwright upgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV - Free Report) to a buy rating in a research note released on Wednesday morning, Marketbeat Ratings reports. HC Wainwright currently has $12.00 price objective on the stock. HC Wainwright also issued estimates for Artiva Biotherapeutics' Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.04) EPS, FY2026 earnings at ($4.09) EPS, FY2027 earnings at ($1.64) EPS, FY2028 earnings at ($1.03) EPS and FY2029 earnings at ($0.63) EPS.

A number of other brokerages have also weighed in on ARTV. Wedbush reaffirmed an "outperform" rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Cantor Fitzgerald cut their target price on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 25th. Finally, Needham & Company LLC cut their target price on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics currently has an average rating of "Buy" and a consensus target price of $17.80.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock traded down $0.07 during trading hours on Wednesday, reaching $1.98. The stock had a trading volume of 176,647 shares, compared to its average volume of 169,494. Artiva Biotherapeutics has a 52 week low of $1.78 and a 52 week high of $17.31. The company has a fifty day simple moving average of $2.12 and a 200-day simple moving average of $5.24.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.15). As a group, equities analysts expect that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN grew its holdings in Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock worth $87,000 after purchasing an additional 3,361 shares during the period. BNP Paribas Financial Markets grew its holdings in Artiva Biotherapeutics by 262.1% in the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock worth $100,000 after purchasing an additional 7,151 shares during the period. Deutsche Bank AG bought a new position in shares of Artiva Biotherapeutics in the fourth quarter worth approximately $216,000. Barclays PLC grew its holdings in shares of Artiva Biotherapeutics by 23.2% during the fourth quarter. Barclays PLC now owns 24,161 shares of the company's stock valued at $244,000 after buying an additional 4,545 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Artiva Biotherapeutics during the fourth quarter valued at approximately $302,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.